Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota
2008
Аутори
Kajander, KajsaMyllyluoma, E.
Rajilić-Stojanović, Mirjana
Kyronpalo, S.
Rasmussen, M.
Jarvenpaa, S.
Zoetendal, Erwin G.
de Vos, Willem M.
Vapaatalo, H.
Korpela, R.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background Irritable bowel syndrome is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial. Aim To investigate the effects of multispecies probiotic supplementation (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium animalis ssp. lactis Bb 12) on abdominal symptoms, quality of life, intestinal microbiota and inflammatory markers in irritable bowel syndrome. Methods Eighty-six irritable bowel syndrome patients (Rome 11 criteria) participated in this randomized, placebo-controlled 5-month intervention. Patients were randomized to receive daily either multispecies probiotic supplementation or placebo. Irritable bowel syndrome symptoms, quality of life, microarray-based intestinal microbiota stability (n = 20), serum cytokines and sensitive C-reactive protein were monitored. Results The composite irritable bowel syndrome score had at 5 months decreased 14 points (95% CI: -19 t...o -9) from baseline with the multispecies probiotic vs. three points (95% CI: -8 to 1) with placebo (P = 0.0083). Especially, distension and abdominal pain were affected. A stabilization of the microbiota was observed, as the microbiota similarity index increased with the probiotic supplementation (1.9 +/- 3.1), while it decreased with placebo (-2.9 +/- 1.7). No differences were seen in C-reactive protein. Conclusions This multispecies probiotic seems to be an effective and safe option to alleviate symptoms of irritable bowel syndrome, and to stabilize the intestinal microbiota.
Извор:
Alimentary Pharmacology & Therapeutics, 2008, 27, 1, 48-57Издавач:
- Wiley, Hoboken
DOI: 10.1111/j.1365-2036.2007.03542.x
ISSN: 0269-2813
PubMed: 17919270
WoS: 000253385300006
Scopus: 2-s2.0-36749082433
Институција/група
Tehnološko-metalurški fakultetTY - JOUR AU - Kajander, Kajsa AU - Myllyluoma, E. AU - Rajilić-Stojanović, Mirjana AU - Kyronpalo, S. AU - Rasmussen, M. AU - Jarvenpaa, S. AU - Zoetendal, Erwin G. AU - de Vos, Willem M. AU - Vapaatalo, H. AU - Korpela, R. PY - 2008 UR - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/1269 AB - Background Irritable bowel syndrome is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial. Aim To investigate the effects of multispecies probiotic supplementation (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium animalis ssp. lactis Bb 12) on abdominal symptoms, quality of life, intestinal microbiota and inflammatory markers in irritable bowel syndrome. Methods Eighty-six irritable bowel syndrome patients (Rome 11 criteria) participated in this randomized, placebo-controlled 5-month intervention. Patients were randomized to receive daily either multispecies probiotic supplementation or placebo. Irritable bowel syndrome symptoms, quality of life, microarray-based intestinal microbiota stability (n = 20), serum cytokines and sensitive C-reactive protein were monitored. Results The composite irritable bowel syndrome score had at 5 months decreased 14 points (95% CI: -19 to -9) from baseline with the multispecies probiotic vs. three points (95% CI: -8 to 1) with placebo (P = 0.0083). Especially, distension and abdominal pain were affected. A stabilization of the microbiota was observed, as the microbiota similarity index increased with the probiotic supplementation (1.9 +/- 3.1), while it decreased with placebo (-2.9 +/- 1.7). No differences were seen in C-reactive protein. Conclusions This multispecies probiotic seems to be an effective and safe option to alleviate symptoms of irritable bowel syndrome, and to stabilize the intestinal microbiota. PB - Wiley, Hoboken T2 - Alimentary Pharmacology & Therapeutics T1 - Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota EP - 57 IS - 1 SP - 48 VL - 27 DO - 10.1111/j.1365-2036.2007.03542.x ER -
@article{ author = "Kajander, Kajsa and Myllyluoma, E. and Rajilić-Stojanović, Mirjana and Kyronpalo, S. and Rasmussen, M. and Jarvenpaa, S. and Zoetendal, Erwin G. and de Vos, Willem M. and Vapaatalo, H. and Korpela, R.", year = "2008", abstract = "Background Irritable bowel syndrome is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial. Aim To investigate the effects of multispecies probiotic supplementation (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium animalis ssp. lactis Bb 12) on abdominal symptoms, quality of life, intestinal microbiota and inflammatory markers in irritable bowel syndrome. Methods Eighty-six irritable bowel syndrome patients (Rome 11 criteria) participated in this randomized, placebo-controlled 5-month intervention. Patients were randomized to receive daily either multispecies probiotic supplementation or placebo. Irritable bowel syndrome symptoms, quality of life, microarray-based intestinal microbiota stability (n = 20), serum cytokines and sensitive C-reactive protein were monitored. Results The composite irritable bowel syndrome score had at 5 months decreased 14 points (95% CI: -19 to -9) from baseline with the multispecies probiotic vs. three points (95% CI: -8 to 1) with placebo (P = 0.0083). Especially, distension and abdominal pain were affected. A stabilization of the microbiota was observed, as the microbiota similarity index increased with the probiotic supplementation (1.9 +/- 3.1), while it decreased with placebo (-2.9 +/- 1.7). No differences were seen in C-reactive protein. Conclusions This multispecies probiotic seems to be an effective and safe option to alleviate symptoms of irritable bowel syndrome, and to stabilize the intestinal microbiota.", publisher = "Wiley, Hoboken", journal = "Alimentary Pharmacology & Therapeutics", title = "Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota", pages = "57-48", number = "1", volume = "27", doi = "10.1111/j.1365-2036.2007.03542.x" }
Kajander, K., Myllyluoma, E., Rajilić-Stojanović, M., Kyronpalo, S., Rasmussen, M., Jarvenpaa, S., Zoetendal, E. G., de Vos, W. M., Vapaatalo, H.,& Korpela, R.. (2008). Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. in Alimentary Pharmacology & Therapeutics Wiley, Hoboken., 27(1), 48-57. https://doi.org/10.1111/j.1365-2036.2007.03542.x
Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyronpalo S, Rasmussen M, Jarvenpaa S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. in Alimentary Pharmacology & Therapeutics. 2008;27(1):48-57. doi:10.1111/j.1365-2036.2007.03542.x .
Kajander, Kajsa, Myllyluoma, E., Rajilić-Stojanović, Mirjana, Kyronpalo, S., Rasmussen, M., Jarvenpaa, S., Zoetendal, Erwin G., de Vos, Willem M., Vapaatalo, H., Korpela, R., "Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota" in Alimentary Pharmacology & Therapeutics, 27, no. 1 (2008):48-57, https://doi.org/10.1111/j.1365-2036.2007.03542.x . .